Protara Updates Interim Results of TARA-002 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy TARA?
Protara Therapeutics "announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Invasive Bladder Cancer with carcinoma in situ or CIS (+/- Ta/T1) who are Bacillus Calmette-Guerin -Unresponsive or BCG-Naive. These results will be featured on Friday, February 27, 2026 during poster sessions at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. The majority of treatment-related adverse events (TRAEs) were Grade 1 and transient with no Grade 3 or greater TRAEs and no related serious adverse events as assessed by study investigators. No patients discontinued treatment due to TRAEs. The most common TRAEs were dysuria, bladder spasm, fatigue and micturition urgency. Most bladder irritations resolved shortly after administration or within a few hours to a few days. Protara expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in the second half of 2026. Enrollment is complete in the BCG-Naive cohort of the ADVANCED-2 trial with 31 patients, and the Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Naive patients in the second half of 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TARA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TARA
Wall Street analysts forecast TARA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.360
Low
23.00
Averages
25.50
High
30.00
Current: 6.360
Low
23.00
Averages
25.50
High
30.00
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Protara Therapeutics Reports Interim Data for TARA-002 in Bladder Cancer Trial
- Clinical Trial Update: Protara Therapeutics reported a 68.2% complete response rate for TARA-002 in its mid-stage trial for non-muscle invasive bladder cancer, leading to a ~22% drop in stock price due to mixed results.
- BCG Response Rates: In the BCG-unresponsive cohort, complete response rates were 68.2% at six months and 33.3% at twelve months, while BCG-naïve patients showed rates of 66.7% and 57.9%, indicating variability in treatment effectiveness.
- Safety Profile: The cell-based therapy maintained a favorable safety and tolerability profile, with no Grade 3 or higher treatment-related adverse events reported, suggesting a lower risk for patients undergoing treatment.
- Future Plans: Protara reaffirmed plans to initiate the ADVANCED-3 registrational trial for BCG-naïve patients in H2 2026, with enrollment in the BCG-unresponsive cohort expected to conclude later this year, demonstrating the company's ongoing commitment to future growth.
See More
Protara Therapeutics Updates TARA-002 Trial Results
- Clinical Trial Response Rate: The ADVANCED-2 trial revealed a 68.2% complete response rate at six months for the BCG-Unresponsive cohort treated with TARA-002, indicating significant therapeutic potential without any Grade 3 or higher treatment-related adverse events reported.
- Response Maintenance Probability: Among responders, the Kaplan-Meier estimated probability of maintaining a complete response for six months was 71.1%, with 100% of patients maintaining their complete response from nine to twelve months, highlighting the drug's promising long-term efficacy.
- BCG Naïve Patient Performance: In the BCG-naïve cohort of 27 patients, the complete response rate was 72.4% at any time and 66.7% at six months, further validating TARA-002's effectiveness across different patient populations and potentially offering new treatment avenues.
- Market Performance Analysis: Protara shares fell 7.94% to $6.84 in premarket trading, trading 12.65% below its 20-day simple moving average, indicating a bearish short-term trend, which suggests that investors should exercise caution.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
Protara's Bladder Cancer Trial Shows Strong Efficacy
- Clinical Trial Results: Protara Therapeutics reported that 68% of BCG-unresponsive patients and 66% of BCG-naive patients were cancer-free at six months in its ongoing Phase 2 Advanced-2 bladder cancer trial, indicating significant efficacy that could enhance the company's market share in bladder cancer treatment.
- Favorable Safety Profile: The trial results demonstrated that TARA-002 has a favorable safety and tolerability profile, with most adverse events being Grade 1 and transient, and no Grade 3 or higher events reported, laying a solid foundation for future clinical applications.
- Market Reaction: Despite a nearly 15% drop in after-hours trading, analysts remain optimistic about the stock, with a 12-month price target of $25.5, suggesting over 240% upside potential from current levels, reflecting confidence in its long-term prospects.
- Future Development Plans: Protara expects to complete enrollment in the Advanced-2 trial cohort by the second half of 2026 and initiate the Advanced-3 registrational trial, further advancing TARA-002's development in high-risk non-muscle invasive bladder cancer populations and enhancing its competitive position in the market.
See More
Protara Updates on TARA-002 Clinical Trial Results
- Clinical Trial Progress: Protara Therapeutics announced interim results from the ADVANCED-2 trial showing a 65.7% complete response rate in the BCG-Unresponsive cohort, indicating TARA-002's potential as a new treatment option for high-risk Non-Muscle Invasive Bladder Cancer patients.
- Efficacy and Safety: Among 35 participants, the complete response rate was 68.2% at six months and 33.3% at twelve months, demonstrating durable efficacy with no Grade 3 or higher treatment-related adverse events, enhancing its appeal as an innovative therapy.
- Future Development Plans: Protara expects to complete enrollment of the BCG-Unresponsive registrational cohort in the second half of 2026 and plans to initiate the ADVANCED-3 registrational trial for BCG-Naïve patients in the same timeframe, further advancing TARA-002's clinical development.
- Industry Impact: The positive results of TARA-002 not only provide clinicians with a new treatment tool but also have the potential to reshape the treatment landscape for Non-Muscle Invasive Bladder Cancer, improving patient quality of life and showcasing Protara's innovative capabilities in the biotechnology sector.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
Protara Therapeutics Reports Interim Data for TARA-002 in Bladder Cancer Trial
- Clinical Trial Update: Protara Therapeutics reported a 68.2% complete response rate for TARA-002 in its mid-stage trial for non-muscle invasive bladder cancer, leading to a ~22% drop in stock price due to mixed results.
- BCG Response Rates: In the BCG-unresponsive cohort, complete response rates were 68.2% at six months and 33.3% at twelve months, while BCG-naïve patients showed rates of 66.7% and 57.9%, indicating variability in treatment effectiveness.
- Safety Profile: The cell-based therapy maintained a favorable safety and tolerability profile, with no Grade 3 or higher treatment-related adverse events reported, suggesting a lower risk for patients undergoing treatment.
- Future Plans: Protara reaffirmed plans to initiate the ADVANCED-3 registrational trial for BCG-naïve patients in H2 2026, with enrollment in the BCG-unresponsive cohort expected to conclude later this year, demonstrating the company's ongoing commitment to future growth.
See More
Protara Therapeutics Updates TARA-002 Trial Results
- Clinical Trial Response Rate: The ADVANCED-2 trial revealed a 68.2% complete response rate at six months for the BCG-Unresponsive cohort treated with TARA-002, indicating significant therapeutic potential without any Grade 3 or higher treatment-related adverse events reported.
- Response Maintenance Probability: Among responders, the Kaplan-Meier estimated probability of maintaining a complete response for six months was 71.1%, with 100% of patients maintaining their complete response from nine to twelve months, highlighting the drug's promising long-term efficacy.
- BCG Naïve Patient Performance: In the BCG-naïve cohort of 27 patients, the complete response rate was 72.4% at any time and 66.7% at six months, further validating TARA-002's effectiveness across different patient populations and potentially offering new treatment avenues.
- Market Performance Analysis: Protara shares fell 7.94% to $6.84 in premarket trading, trading 12.65% below its 20-day simple moving average, indicating a bearish short-term trend, which suggests that investors should exercise caution.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
Protara's Bladder Cancer Trial Shows Strong Efficacy
- Clinical Trial Results: Protara Therapeutics reported that 68% of BCG-unresponsive patients and 66% of BCG-naive patients were cancer-free at six months in its ongoing Phase 2 Advanced-2 bladder cancer trial, indicating significant efficacy that could enhance the company's market share in bladder cancer treatment.
- Favorable Safety Profile: The trial results demonstrated that TARA-002 has a favorable safety and tolerability profile, with most adverse events being Grade 1 and transient, and no Grade 3 or higher events reported, laying a solid foundation for future clinical applications.
- Market Reaction: Despite a nearly 15% drop in after-hours trading, analysts remain optimistic about the stock, with a 12-month price target of $25.5, suggesting over 240% upside potential from current levels, reflecting confidence in its long-term prospects.
- Future Development Plans: Protara expects to complete enrollment in the Advanced-2 trial cohort by the second half of 2026 and initiate the Advanced-3 registrational trial, further advancing TARA-002's development in high-risk non-muscle invasive bladder cancer populations and enhancing its competitive position in the market.
See More
Protara Updates on TARA-002 Clinical Trial Results
- Clinical Trial Progress: Protara Therapeutics announced interim results from the ADVANCED-2 trial showing a 65.7% complete response rate in the BCG-Unresponsive cohort, indicating TARA-002's potential as a new treatment option for high-risk Non-Muscle Invasive Bladder Cancer patients.
- Efficacy and Safety: Among 35 participants, the complete response rate was 68.2% at six months and 33.3% at twelve months, demonstrating durable efficacy with no Grade 3 or higher treatment-related adverse events, enhancing its appeal as an innovative therapy.
- Future Development Plans: Protara expects to complete enrollment of the BCG-Unresponsive registrational cohort in the second half of 2026 and plans to initiate the ADVANCED-3 registrational trial for BCG-Naïve patients in the same timeframe, further advancing TARA-002's clinical development.
- Industry Impact: The positive results of TARA-002 not only provide clinicians with a new treatment tool but also have the potential to reshape the treatment landscape for Non-Muscle Invasive Bladder Cancer, improving patient quality of life and showcasing Protara's innovative capabilities in the biotechnology sector.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
